I have been prescribed Xarelto® (rivaroxaban) to either treat DVT or PE, or prevent them from recurring

Patients with Deep Vein Thrombosis or Pulmonary Embolism who’ve been prescribed Xarelto

This section of the website is intended for patients prescribed Xarelto in the UK to provide information on its uses. It is not intended to replace in anyway the opinion of a healthcare professional.

You have been diagnosed with a Deep Vein Thrombosis (DVT) or Pulmonary embolism (PE) and have been prescribed Xarelto to reduce the likelihood of more clots forming.

The Frequently Asked Questions (FAQs) presented on this website are to support your understanding to take Xarelto correctly and to treat blood clots in the veins in your legs or in the vessels of your lungs, and to prevent clots from re-occurring in the blood vessels of your legs and/or lungs.

If you have further questions surrounding the use of Xarelto, please ask your doctor, pharmacist or nurse who will be able to answer these and provide you with more information as appropriate.

For a full list of possible side effects please see the Patient Information Leaflet included in the pack with a medicine.

To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget

Report Possible Side Effects

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.

You can also report side effects and quality complaints to Bayer Plc. Further information is available on the “contact” tab at www.bayer.co.uk.

By reporting side effects you can help provide more information on the safety of this medicine.